Comparing Pneumococcal Vaccines and CDC Recommendations for Adults

EP: 1.Epidemiology and High-Risk Populations for Pneumococcal Disease

Now Viewing

EP: 2.Comparing Pneumococcal Vaccines and CDC Recommendations for Adults

EP: 3.Updated Evidence-Based Recommendations for Pneumococcal Conjugate Vaccines

EP: 4.Pharmacist’s Guide: Choosing the Most Appropriate Pneumococcal Vaccine for Patients

EP: 5.Risk vs. Benefit of Pneumococcal Vaccines: Shared Clinical Decision-Making for Patients and Pharmacists

EP: 6.Pneumococcal Vaccine Patient Education: What Pharmacists Should Know and Share

Pneumococcal Vaccine Comparison and CDC Recommendations Summary

Four distinct pneumococcal vaccines are currently available, each providing protection against different serotypes of Streptococcus pneumoniae. Three conjugate vaccines—PCV-15, PCV-20, and PCV-21—begin with "PCV" (pneumococcal conjugate vaccine), while the polysaccharide vaccine is PPSV-23 (23-valent pneumococcal polysaccharide vaccine). The fundamental difference lies in their immune response mechanisms: PPSV-23 consists of large sugar molecules without protein components, activating only B cells, while conjugate vaccines combine sugar molecules with proteins to engage both B and T cells, creating stronger and longer-lasting immunity. PCV-20 covers the same serotypes as PCV-15 plus five additional ones, whereas PCV-21 targets 11 different serotypes than PCV-20, excluding 10 serotypes found in PCV-20 but including eight unique serotypes not present in other vaccines.

Serotype coverage considerations significantly impact vaccine selection based on regional disease patterns. Serotype 4, notably absent from PCV-21, causes high percentages of invasive disease in western United States regions including Alaska, Colorado, New Mexico, Navajo Nation, and Oregon, particularly among adults under 65 with specific risk factors like alcohol use disorder, chronic lung disease, cigarette smoking, homelessness, or injection drug use. When serotype 4 accounts for 30% or more of invasive pneumococcal disease in a population, PCV-20 or PCV-15 is recommended over PCV-21. Conversely, PCV-21's eight unique serotypes may provide better coverage for circulating strains in many US settings, making it more suitable for targeting adult populations at risk from those specific serotypes.

Current CDC recommendations have undergone six changes in just three years due to new vaccine approvals. Pneumococcal vaccination is now recommended for all adults aged 50 years and older, representing a significant recent expansion from previous age-based guidelines. Risk-based recommendations apply to adults aged 19-49 years with specific medical conditions including immunocompromising conditions, chronic kidney disease, asplenia, cerebrospinal fluid leaks, cochlear implants, alcohol use disorder, chronic heart disease, chronic liver disease, chronic lung diseases including COPD and adult asthma, cigarette smoking, and diabetes. The CDC's PneumoRex Vax Advisor app provides essential guidance for navigating these complex and frequently changing recommendations.